|Articles|March 15, 2007
Wet AMD treatment approved in Europe
Toronto-Novadaq Technologies said the European Union has approved the OPTTX System, a minimally invasive treatment for wet age-related macular degeneration.
Advertisement
Toronto-Novadaq Technologies said the European Union has approved the OPTTX System, a minimally invasive treatment for wet age-related macular degeneration.
The company is initiating post-market patient registry studies.
The diagnostic and therapeutic system uses a proprietary imaging technology to identify the disease state, then offers targeted treatment via choroidal vessel closure, which can be done alone or in combination with anti-VEGF therapy.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Last year in glaucoma at EnVision Summit 2025
4
Looking back at the 2025 EnVision Summit
5
























